A Different Corner of the DNA Stack

10x Genomics (TXG) sits in the broader DNA-reading field that Adam O’Dell’s Imperium pitch builds on, but it is not one of the promo’s picks. The pitch centers on Twist Bioscience and Ginkgo Bioworks (DNA), with Absci as the apps layer. 10x Genomics is a comparison name, a way to understand the wider field around the theme, and it occupies a distinct corner of that field.

Where Twist writes DNA and Ginkgo programs it, 10x Genomics profiles it. The company makes tools for reading and analyzing biology at the level of individual cells, a layer of detail that older sequencing methods could not easily reach.

What Single-Cell and Spatial Genomics Do

The core of 10x Genomics is single-cell and spatial genomics. In plain terms, single-cell work lets researchers look at gene expression one cell at a time, rather than averaging a whole sample together. A tumor, for example, is not one uniform thing; it is a mix of many different cell types. Single-cell tools reveal that mix, which matters for understanding how diseases actually behave.

Spatial genomics adds the “where.” It shows not just which genes are active but where in a tissue sample they are active. That combination, what is happening and where, is valuable for drug discovery, cancer research, and developmental biology, and it is the kind of capability that fits naturally into the read side of the DNA-as-software thesis.

How It Compares to the Promo’s Names

The difference between 10x Genomics and the promo’s picks is instructive. Twist is a synthesis company, a writer of DNA, and O’Dell casts it as the silicon layer. 10x Genomics is a tools company on the read side, closer in kind to the sequencing names. A synthesis pure-play and a single-cell profiling company face different customers, different competitive dynamics, and different economics, even though both sit under the synthetic-biology umbrella.

10x Genomics also sits in a crowded competitive set. The broader tools and sequencing field includes Illumina, Pacific Biosciences, Thermo Fisher, and Danaher, and these are well-funded, established players. That is part of the context any investor should understand before weighing the name.

The Framing Question

O’Dell’s pitch leans on the idea that the number one Imperium company is “over 600 times smaller than Nvidia” with a path to becoming the biggest company in the world. That framing is aimed at the microcap end of the field, and it is a claim worth discounting; being smaller than Nvidia is not, by itself, an opportunity. 10x Genomics is not part of that specific framing, which is precisely why it is useful as a comparison: it shows the range of companies that the broader theme touches, from the picks O’Dell actually names to the tools competitors that sit beside them.

For the names at the center of the pitch, see our Twist Bioscience stock piece and our Ginkgo Bioworks stock piece. For the reading technology itself, our next-generation sequencing explainer covers the field in more detail.

O’Dell’s track record is real; he teased Palantir in the $20s in spring 2024 and watched it become the best-performing S&P 500 stock of 2024. But the Imperium theme is a refreshed version of a pitch he has run since 2021, and the individual names underneath it have changed over time. 10x Genomics is best understood as part of the wider field the theme describes, a reading-side tools company worth knowing about even though it is not the pick being sold.

Why the Comparison Matters

The reason to study 10x Genomics alongside the Imperium pitch is that it clarifies what the pitch is actually selling. O’Dell’s picks are writers and programmers of DNA, the companies that make the code and run the software. 10x Genomics is a reader, and specifically a high-resolution reader that shows what is happening inside individual cells. All of these companies need each other in a sense: a written sequence is only useful if you can read and verify what it does, and reading is only useful if the data lands in tools that can interpret it.

That interdependence is part of what makes the synthetic-biology theme credible as a theme, rather than as a single stock story. It is a field with many companies doing complementary work, from synthesis to sequencing to profiling to software. The risk for any single name is that it occupies a slice of that field while the pitch implies it owns the whole thing.

10x Genomics also helps calibrate the competition. The read side is not a wide-open space; it is populated by Illumina, Pacific Biosciences, Thermo Fisher, and Danaher, all well funded and established. A reader weighing 10x Genomics should think about how its single-cell and spatial niche holds up against those larger tools companies, and should remember that the Imperium pitch itself points at different names entirely.

Ready to see the research? Click here to access Adam O’Dell’s report.


NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.